NMN gummies hit shelves after the FDA reversal — while a meta-analysis finds no metabolic benefit
Vitafusion launched Vital NMN gummies on September 16, 2026, riding the wave of the FDA's late-2025 NMN reversal — the regulatory shift that reopened the US market for nicotinamide mononucleotide supplements. The timing is commercial; the science is not cooperating.
What does the 2026 meta-analysis say?
A systematic review in Nutrients pooled 15 randomized controlled trials (383 participants) and found NMN safe but with no significant effects on body weight, fasting glucose or lipids — and only a modest, non-significant trend on insulin resistance. Those are precisely the metabolic outcomes NMN marketing leans on.
But doesn't NMN raise NAD+?
Yes — NMN reliably raises NAD+ levels, and that much is established. The gap is between the biomarker and the benefit: raising NAD+ has not translated into measured metabolic or anti-aging outcomes in humans.
How does this connect to mitochondrial health?
NAD+ is central to mitochondrial energy metabolism, which is why NAD+ boosters are sold on mitochondrial promises. The meta-analysis is a reminder that a molecule's mitochondrial plausibility is not the same as a demonstrated mitochondrial benefit in people.
Where the evidence stands
- Established: NMN raises NAD+ levels in humans and has a clean safety record in trials.
- Established: A 2026 systematic review of 15 RCTs found no significant metabolic benefits — the claimed benefits are absent in the pooled human data.
- Absent: There is no human evidence that NMN improves mitochondrial function, extends healthspan or extends lifespan.